# TAKEDA PHARMACEUTICAL CO LTD

> Institutional holdings reported to the SEC as of Q3 2025 on Form 13F. CIK 1395064. Source: https://holderbook.com/funds/1395064-takeda-pharmaceutical-co-ltd/

- Reported value: $16.4M
- Positions: 8
- Weight of the ten largest: 100.0%
- Filed: 2025-11-13

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| OVID THERAPEUTICS INC | [OVID](https://holderbook.com/stocks/OVID/) | $9.8M | 7,531,996 | 59.8% | 8 |
| EQUILLIUM INC | [EQ](https://holderbook.com/stocks/EQ/) | $2.6M | 1,824,977 | 15.9% | 8 |
| XILIO THERAPEUTICS INC | [XLO](https://holderbook.com/stocks/XLO/) | $1.2M | 1,475,121 | 7.6% | 8 |
| SHATTUCK LABS INC | [STTK](https://holderbook.com/stocks/STTK/) | $1.2M | 515,619 | 7.5% | 8 |
| LYELL IMMUNOPHARMA INC | [LYELXXXX](https://holderbook.com/stocks/LYELXXXX/) | $891.4K | 54,887 | 5.4% | 4 |
| AMERICAN WELL CORP | [AMWL](https://holderbook.com/stocks/AMWL/) | $478.1K | 77,733 | 2.9% | 8 |
| RANI THERAPEUTICS HLDGS INC | [RANI](https://holderbook.com/stocks/RANI/) | $101.6K | 203,190 | 0.6% | 8 |
| STANDARD BIOTOOLS INC | [LAB](https://holderbook.com/stocks/LAB/) | $21.5K | 16,515 | 0.1% | 8 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2025 | +63.4% | +10.5% | +52.9% | 100% |
| Q1 2025 | -39.0% | -4.6% | -34.5% | 100% |
| Q4 2024 | +11.5% | +2.1% | +9.4% | 100% |
| Q3 2024 | -12.5% | +5.4% | -18.0% | 100% |
| Q2 2024 | -11.8% | +4.0% | -15.9% | 100% |
| Q1 2024 | +5.9% | +10.0% | -4.2% | 97% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q3 2025 | $16.4M | 8 |
| Q2 2025 | $19.6M | 11 |
| Q1 2025 | $16.2M | 11 |
| Q4 2024 | $26.6M | 11 |
| Q3 2024 | $38.0M | 10 |
| Q2 2024 | $232.3M | 13 |
| Q1 2024 | $289.0M | 15 |
| Q4 2023 | $327.5M | 14 |